Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.[1][2][3]

Iomeprol was approved for medical use in the United States in November 2024.[1][4][5]

Side effects

It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.[2] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.[2]

Society and culture

Iomeprol is not metabolized in the human body but excreted in unchanged form.[medical citation needed] It is decomposed slowly and can therefore accumulate in the environment.[6]

Iomeprol was approved for medical use in the United States in November 2024.[1][4]

Brand names

Iomeprol is sold under the brand name Iomervu.[1]

References

  1. ^ a b c d e https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216017s000,216017s000lbl.pdf
  2. ^ a b c Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. ISBN 978-1-875098-30-9. OCLC 869772940.
  3. ^ Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.
  4. ^ a b "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
  5. ^ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
  6. ^ Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, et al. (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.


Allikas: https://en.wikipedia.org/wiki/Iomeprol
No tags for this post.